Theravance Biopharma (NASDAQ:TBPH) Hits New 52-Week High on Analyst Upgrade

Key Points

• Theravance Biopharma shares hit a new 52-week high of $14.21, with the stock last trading at $13.86 after closing at $13.15.
• Analysts are optimistic, with BTIG Research raising its target price to $25.00 and a "buy" rating, while Wall Street Zen and Jones Trading upgraded the stock to "strong-buy."
• Institutional investors own 99.10% of Theravance Biopharma, with several firms increasing their holdings in recent quarters.

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) hit a new 52-week high on Monday after Zacks Research upgraded the stock from a hold rating to a strong-buy rating. The company traded as high as $14.21 and last traded at $13.86, with a volume of 117715 shares trading hands. The stock had previously closed at $13.15.

A number of other research analysts also recently weighed in on the company. Jones Trading upgraded Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target on the stock in a report on Tuesday, June 17th. BTIG Research lifted their price target on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a report on Friday, June 27th. Finally, Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Strong Buy" and an average target price of $21.33.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of the business's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $11.39, for a total value of $113,900.00. Following the completion of the sale, the senior vice president owned 326,918 shares of the company's stock, valued at $3,723,596.02. The trade was a 2.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 44,000 shares of company stock valued at $491,800 over the last ninety days. 6.90% of the stock is owned by insiders.

Institutional Trading of Theravance Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Aquatic Capital Management LLC acquired a new stake in shares of Theravance Biopharma in the fourth quarter worth about $25,000. GAMMA Investing LLC boosted its stake in Theravance Biopharma by 1,201.8% during the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 3,281 shares during the period. Tower Research Capital LLC TRC boosted its stake in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock valued at $55,000 after purchasing an additional 781 shares during the period. AQR Capital Management LLC bought a new stake in Theravance Biopharma during the 1st quarter valued at approximately $101,000. Finally, R Squared Ltd boosted its stake in Theravance Biopharma by 636.6% during the 1st quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock valued at $112,000 after purchasing an additional 10,822 shares during the period. Institutional investors and hedge funds own 99.10% of the company's stock.

Theravance Biopharma Stock Performance

The firm has a 50 day moving average of $11.48 and a two-hundred day moving average of $10.13. The stock has a market cap of $700.51 million, a P/E ratio of 57.96 and a beta of 0.01.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.